| 1. Domain | 1.1 Scope of the Domain | Boundaries | The range of phenomena the science includes and excludes. | Focuses on how cells detect, transmit, amplify, integrate, and respond to information via chemical, electrical, and mechanical signals. Includes receptor activation, signal transduction cascades, second messengers, phosphorylation networks, ligand–receptor interactions, and cell–cell communication. Excludes organism-level neural circuitry or hormonal physiology except where rooted in intracellular signaling principles. |
| | Scale | The spatial, temporal, or organizational level at which the science operates (e.g., quantum, cellular, social, cosmic). | Operates at molecular–cellular scales: nanometer interactions (ligand binding), sub-second signaling events, multi-second or minute-long cascades, and spatial signaling domains within micrometer-sized cells. |
| 1.2 Ontological Commitments | Entities | The kinds of things assumed to exist within the domain (particles, organisms, agents, fields, etc.). | Receptors (GPCRs, RTKs), ligands, intracellular messengers (Ca²⁺, cAMP, IP₃), GTPases, kinases, phosphatases, scaffolding proteins, transcription factors, junctional complexes, electrical synapse components. |
| | Properties | The fundamental attributes these entities possess (mass, charge, genotype, preference, etc.). | Binding affinity, signal strength, amplification potential, phosphorylation state, activation thresholds, diffusion rates, residence times, conformational states, cooperativity, spatial localization, and feedback sensitivity. |
| | Categories | The basic ontological types used to classify domain elements (substances, processes, relations, structures). | Signaling types (autocrine, paracrine, juxtacrine, endocrine), pathway families (GPCR, RTK, Wnt, Notch, TGF-β, NF-κB), messenger classes (ions, nucleotides, lipids), and regulatory modes (feedback, feedforward, cross-talk). |
| 1.3 State-Variables | Variables | The measurable or definable properties that describe system conditions. | Ligand concentration, receptor occupancy, phosphorylation levels, second-messenger abundance, activation probabilities, diffusion coefficients, pathway flux, transcriptional output, feedback strength. |
| | Parameterization | How variables encode and represent the system’s state. | State described by dynamic concentration profiles, activation curves, kinetic rate constants, spatial gradients, interaction networks, and temporal trajectories of signaling activities. |
| 1.4 Admissible Idealizations | Simplifications | Conceptual reductions used to make the domain tractable (point masses, rational agents, perfect gases). | Receptors treated as binary on/off switches; linearizing nonlinear cascades; well-mixed approximations; reducing networks into canonical modules; ignoring stochastic fluctuations; treating membrane domains as uniform. |
| | Validity Conditions | The limits and contexts in which idealizations hold or break down. | Idealizations break down when signaling is highly nonlinear, when spatial microdomains dominate behavior, when stochastic noise is large (low molecule counts), when receptor clustering or scaffolding strongly affects outcome. |
| 1.5 Domain Assumptions | Structural Assumptions | Background ontological stances such as determinism, continuity, randomness, discreteness. | Signaling follows biochemical kinetics; information flow is directional; pathways maintain conserved identity; feedback loops regulate amplitude/duration; ligand–receptor interactions follow thermodynamic/kinetic principles. |
| | Implicit Commitments | Unstated but necessary assumptions that shape the field’s conceptual structure. | Assumes receptor fidelity, stable messenger identity, reliable phosphorylation/dephosphorylation cycles, consistent diffusion environments, and that noise remains biologically manageable. |
| 1.6 Internal Coherence Requirements | Consistency | The demand that domain concepts do not contradict one another. | Binding rules, kinetic laws, and pathway architectures cannot contradict one another; cross-talk must respect biochemical compatibility; amplification must align with energy and stoichiometric constraints. |
| | Compatibility | The requirement that entities, variables, and assumptions fit together into a unified descriptive framework. | Receptors, messengers, scaffolds, enzymes, feedback loops, and downstream transcriptional responses must integrate into one unified network that remains coherent across spatial and temporal scales. |
| 2. Evidence Layer | 2.1 Observable Phenomena | Observables | The aspects of the domain that can produce detectable signals accessible to measurement. | Ligand–receptor binding events, receptor clustering, phosphorylation changes, second-messenger pulses (Ca²⁺ spikes, cAMP waves), activation of kinases or transcription factors, membrane potential changes, synaptic release, cell–cell junction signaling, reporter-gene activation. |
| | Detection Limits | The boundaries of what can be resolved or sensed by current instruments or methods. | Constrained by imaging resolution (~200 nm optical; 20–50 nm super-resolution; 1–2 nm EM), temporal sampling (ms–s for Ca²⁺ transients), and sensitivity of fluorescent sensors; single-molecule events may fall below detection thresholds. |
| 2.2 Measurement Systems | Units | Standardized quantifications (meters, seconds, volts, decibels, dollars, etc.) necessary for consistent comparison. | Concentration (nM–µM), fluorescence intensity units, phosphorylation percentage, ion concentration (nM–mM), membrane potential (mV), kinetic rates (s⁻¹), diffusion coefficients (µm²/s), gene-expression fold change. |
| | Instruments | Devices and tools (microscopes, spectrometers, sensors, surveys, detectors) used to produce measurements. | Fluorescence microscopes, confocal and super-resolution systems, FRET/FLIM sensors, calcium imaging systems, electrophysiology rigs (patch-clamp), flow cytometers, Western blot and mass-spec phosphoproteomics platforms, reporter assays, biosensors. |
| 2.3 Operational Definitions | Definitions | Terms defined by specific measurement procedures, ensuring empirical clarity. | Receptor activation defined by conformational change or phosphorylation; Ca²⁺ signaling defined by amplitude/frequency of spikes; downstream activation defined by nuclear translocation; gene-output defined by reporter signal intensity. |
| | Procedures | The explicit steps required to perform a measurement in a reproducible way. | Ligand addition assays, FRET-based conformational measurements, calcium dye loading, electrophysiological recording steps, standard phospho-blot workflows, time-lapse imaging, stimulation–response curves, reporter-gene quantification. |
| 2.4 Data Acquisition | Protocols | Formal processes for gathering data under controlled or standardized conditions. | Controlled ligand dosing, standardized illumination/exposure, fixed time-interval imaging, replicated stimulation trials, calibration before acquisition, parallel measurement of controls, consistent sensor expression. |
| | Sampling | Rules determining which subset of the domain is measured and how representative it is. | Selecting representative cells or regions; ensuring sufficient timepoints for transient signaling events; capturing spatial gradients; accounting for cell-cycle variability; choosing sample sizes adequate for stochastic signaling. |
| 2.5 Data Character & Format | Data Types | The form raw evidence takes (time series, spectra, images, counts, qualitative records). | Time-series fluorescence traces, FRET efficiency curves, electrophysiology recordings, phosphoprotein band intensities, mass-spec spectral data, single-cell signaling distributions, spatial activation maps, gene-reporter intensities. |
| | Resolution | The granularity or precision with which data is captured. | Spatial resolution dictated by microscopy modality; temporal resolution from ms (ion spikes) to minutes (transcriptional output); intensity resolution limited by sensor noise, photon count, and detector dynamic range. |
| 2.6 Reliability & Calibration | Calibration | Adjustment procedures ensuring instruments produce accurate results. | Fluorescence reference standards, electrophysiology calibration, FRET stoichiometry corrections, Ca²⁺ sensor calibration curves, antibody specificity validation, exposure/gain normalization, instrument drift correction. |
| | Error Characterization | Identification and quantification of noise, uncertainty, bias, and measurement error. | Identifying noise from photobleaching, dye variability, nonspecific binding, stochastic fluctuations in low-copy messengers, motion artifacts, drift, background fluorescence, sampling bias; quantifying random vs systematic error. |
| 3. Structural Layer | 3.1 Patterns & Regularities | Laws / Relations | Stable, repeatable patterns governing how observables behave across conditions. | Ligand–receptor interactions obey saturation kinetics; signaling amplitude and duration follow predictable dose–response behaviors; second messengers propagate in waves or pulses; cascades exhibit amplification, adaptation, and feedback regulation; pathway cross-talk follows conserved interaction rules. |
| | Invariants | Quantities or properties that remain constant under transformations (symmetries, conservation laws). | Conserved receptor architecture (e.g., 7-pass GPCRs, RTK dimerization), stable kinetic motifs (feedforward loops, negative feedback), constant ligand-binding stoichiometry, reproducible phosphorylation cycles, and conserved second-messenger behaviors across species. |
| 3.2 Causal Architecture | Mechanisms | Underlying processes or structures that produce the observed regularities. | Ligand binding drives conformational change; kinases/phosphatases toggle pathway states; GTPases cycle between active/inactive forms; scaffolds localize components; mechanical or electrical stimuli open channels; signals transmit through cascades of biochemical modifications. |
| | Pathways | Organized sequences of interactions forming a causal chain or network. | Canonical routes such as GPCR → G protein → effector → second messenger; RTK → Ras/MAPK; PI3K → AKT; Ca²⁺ influx → calmodulin → kinase activation; Notch receptor cleavage → transcription; Wnt → β-catenin stabilization. |
| 3.3 Theoretical Vocabulary | Concepts | Core terms that encode the domain’s structure (force, gene, equilibrium, field). | Signal transduction, amplification, desensitization, cooperativity, cross-talk, thresholds, oscillations, scaffolding, feedback control, second messengers, receptor activation curves, transcriptional response. |
| | Classifications | Taxonomies, categories, or typologies that organize entities and relations. | Signaling modes (autocrine, paracrine, endocrine, juxtacrine), receptor classes (GPCRs, RTKs, nuclear receptors), pathway families (MAPK, PI3K, NF-κB, JAK/STAT), messenger types (ions, lipids, nucleotides), and kinetic motifs (switches, oscillators, bistable systems). |
| 3.4 Formal Representations | Equations | Mathematical constructs expressing laws, relations, or mechanisms. | Ligand-binding kinetics equations, Michaelis–Menten forms, Hill functions for cooperativity, ODE systems for cascade dynamics, diffusion equations for messenger spread, threshold equations for activation or oscillation. |
| | Models | Structured representations—mathematical, computational, or conceptual—used to predict and explain phenomena. | Network models of signaling cascades, systems of coupled ODEs, stochastic models for low-copy messengers, spatial reaction–diffusion models, receptor occupancy simulations, Boolean or logic models for pathway activation states. |
| 3.5 Idealized Structures | Simplified Models | Purposeful abstractions that capture essential dynamics while omitting irrelevant detail. | Receptors treated as simple binary switches; cascades reduced to linear chains; well-mixed cytosol assumption; ignoring subcellular spatial heterogeneity; treating feedback loops as single-parameter modifiers. |
| | Limit Conditions | Regimes where specific models or approximations hold (classical vs. quantum, linear vs. nonlinear). | Idealizations break down when spatial gradients dominate, when signaling is stochastic at low molecule counts, when receptor clustering or scaffolding is essential, or when nonlinear feedback strongly shapes system behavior. |
| 3.6 Integrative Frameworks | Unifying Theories | Higher-order structures that connect disparate laws or mechanisms under a coherent whole. | Signaling viewed as an information-processing network integrating ligand detection, dynamic amplification, spatial organization, and gene regulation; cross-pathway integration forms coherent cellular decision-making systems. |
| | Interdisciplinary Links | Points where the theory connects to adjacent sciences or larger explanatory systems. | Connects to biophysics (binding energetics, diffusion), systems biology (network dynamics), neuroscience (synaptic signaling principles), immunology (cytokine networks), endocrinology (hormone signaling), and developmental biology (pattern formation). |
| 4. Method Layer | 4.1 Inquiry Design | Experimental Design | Structured plans for manipulating variables to test causal claims. | Perturbing ligand concentration, modifying receptor expression, inhibiting or activating kinases/phosphatases, blocking Ca²⁺ channels, altering feedback loops, or introducing synthetic ligands to determine causal effects on pathway activation and downstream signaling responses. |
| | Observational Design | Systematic approaches for gathering non-manipulated data (surveys, field studies, natural experiments). | Monitoring spontaneous signaling fluctuations, endogenous transcription-factor activation, natural Ca²⁺ oscillations, receptor clustering, or pathway cross-talk without imposing perturbations. |
| 4.2 Testing & Validation | Hypothesis Testing | Procedures for evaluating whether evidence supports or contradicts specific claims. | Comparing predicted activation curves to empirical responses; testing whether pathway inhibition produces expected changes; validating phospho-state predictions; evaluating dose–response curves; testing models of oscillations, thresholds, or feedback control. |
| | Replication | The requirement that results be independently reproducible under similar conditions. | Repeating ligand stimulation trials, phosphorylation assays, calcium imaging sessions, FRET/FLIM measurements, and gene-reporter assays under the same conditions to ensure reliable, reproducible signaling dynamics. |
| 4.3 Inference & Evaluation | Statistical Inference | Rules for drawing conclusions from noisy or incomplete data. | Quantifying noise in Ca²⁺ spikes or phosphorylation cycles; evaluating significance of dose–response differences; fitting kinetic parameters; inferring activation thresholds; analyzing stochastic fluctuations in low-copy signaling components. |
| | Model Comparison | Criteria (fit, simplicity, predictive accuracy, robustness) used to evaluate competing models. | Comparing ODE signaling models, stochastic models, diffusion-based models, and Boolean pathway representations based on accuracy, predictive strength, robustness to noise, and explanatory power. |
| 4.4 Error Management | Error Analysis | Identification and quantification of random and systematic errors. | Identifying sources of error from photobleaching, sensor saturation, ligand depletion, antibody variability, drift, background fluorescence, and stochastic noise; quantifying random vs systematic error in signaling measurements. |
| | Bias Control | Methods for minimizing subjective, instrumental, or procedural biases. | Standardizing sensor expression, controlling ligand dosing, mitigating phototoxicity, blinding image quantification, validating antibodies and fluorescent probes, and correcting for detector drift. |
| 4.5 Adjudication & Revision | Peer Scrutiny | Collective evaluation of claims through critique, review, and debate. | Reviewing pathway models, imaging protocols, FRET/FLIM analysis pipelines, electrophysiology data, and phospho-profiling workflows through lab group review, peer review, replication by independent labs, and reanalysis of raw data. |
| | Theory Revision | Procedures for modifying, replacing, or discarding models based on new evidence. | Updating pathway diagrams, kinetic models, or mechanistic assumptions when new evidence reveals cross-talk, hidden feedback loops, receptor clustering effects, or alternative signaling routes. |
| 4.6 Integrity Conditions | Transparency | Requirements to disclose methods, data, assumptions, and limitations. | Detailed reporting of stimulation protocols, imaging parameters, sensor characteristics, data-processing algorithms, normalization strategies, and all analytical assumptions. |
| | Ethical Standards | Norms ensuring responsible conduct in experimentation, data handling, and publication. | Ensuring responsible use of genetic manipulation, reporting data honestly without selective omission, preventing misinterpretation of signaling outputs, and employing ethically appropriate cell model systems. |